Cyclerion Therapeutics (KRSA) Projected to Announce Quarterly Earnings on Wednesday

Cyclerion Therapeutics (NASDAQ:KRSA) is anticipated to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect Cyclerion Therapeutics to announce earnings of ($50.40) per share and revenue of $0.55 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Cyclerion Therapeutics Stock Performance

Cyclerion Therapeutics stock traded down $0.46 during trading on Wednesday, reaching $31.50. 11,584 shares of the company were exchanged, compared to its average volume of 280,134. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -2.74 and a beta of 1.85. Cyclerion Therapeutics has a 52-week low of $7.19 and a 52-week high of $59.36.

Wall Street Analysts Forecast Growth

KRSA has been the subject of several analyst reports. Zacks Research raised shares of Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday, September 9th. TD Cowen started coverage on Cyclerion Therapeutics in a report on Monday, September 14th. They set a “buy” rating for the company. UBS Group began coverage on shares of Cyclerion Therapeutics in a report on Friday, September 11th. They issued a “buy” rating and a $55.00 price objective on the stock. Wall Street Zen upgraded shares of Cyclerion Therapeutics to a “sell” rating in a research report on Saturday, October 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Cyclerion Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $53.00.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system and cardiopulmonary diseases. The company’s research centered on soluble guanylate cyclase (sGC) stimulators, a class of compounds intended to regulate cellular signaling and potentially address diseases associated with impaired nitric oxide signaling.

Cyclerion was formed in 2019 as a spin-off from Ironwood Pharmaceuticals. Its historical development portfolio included olinciguat, an investigational treatment studied for sickle cell disease, and praliciguat, which was evaluated for conditions including diabetic nephropathy and nonalcoholic steatohepatitis.